Successful research in targeted protein degradation depends not only on measurements at high sensitivity, speed and precision ...

This review highlights the critical role of ubiquitination in governing the functionality of cancer stem cells (CSCs), ...

E3-ubiquitin ligase inducible degrader of the LDL receptor has a similar function to PCSK9 and is a potential therapeutic target. A desirable treatment target for HoFH patients is LDL-C ≤1.8 mmol/l.

Shenzhen Zhongge Biotechnology Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an interleukin-1 ...

Trimtech Therapeutics has closed a seed funding round of $31m (£25m) to advance its pipeline of CNS penetrant therapeutics.

TRIMTECH Therapeutics’s incredible $31million seed funding haul will be deployed to develop treatments for severe ...

During ubiquitination, a group of enzymes called E3 ubiquitin ligases attach a small protein called ubiquitin to other proteins. This tagging, in turn, helps determine the fate of the targeted ...

Katalytic Therapeutics Inc. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a phosphodiesterase PDE4-targeting ...

TRIMTECH Therapeutics raises $31M to enhance its TRIMTAC platform, targeting protein aggregates in neurodegenerative diseases for improved therapeutic outcomes.

This review highlights the critical role of ubiquitination in governing the functionality of cancer stem cells (CSCs), ...